HUMACYTE, INC.: H.C. Wainwright raises target price to $4 from $3

H.C. Wainwright has raised its price target for Humacyte, Inc. (NASDAQ:HUMA) to $4.00 per share from $3.00, while maintaining its "Buy" rating. The stock currently trades at $1.13, reflecting a 17.65% increase year-to-date, although it remains down nearly 40% over the past year. The firm cited the company’s V012 Phase 3 trial of ATEV versus AV fistula in female hemodialysis patients on June 11 at the SVS Vascular Annual Meeting in Boston. This interim analysis will evaluate the first 80 of 120 enrolled patients at the one-year follow-up timepoint. The trial protocol allows for early stopping if ATEV demonstrates clear superiority over the standard of care fistula. Should the results be favorable, Humacyte plans to file a supplemental BLA in the second half of 2026, incorporating data from both the V012 and V007 trials. The company’s Regenerative Medicine Advanced Therapy designation may facilitate an accelerated regulatory review. H.C. Wainwright anticipates a potential launch of ATEV in the dialysis market by the third quarter of 2027. Despite a recent earnings report showing a mixed financial performance, including a $0.09 loss per share and revenue significantly below expectations, the firm remains optimistic about long-term prospects.